Healionics is a clinical-stage company addressing the critical need for improved means of dialysis access in patients with kidney failure. Our STARgraft vascular graft (artificial blood vessel) resists the problems of occlusion and infection suffered by current grafts. We also have an exciting product pipeline based on our platform STAR® biomaterial which — given its unique ability to prevent both scarring and infection — can enable new types of implantable devices and improve the performance of many existing ones. The Seattle-based company has 33 patents issued or pending, has completed a first human study of STARgraft, and is raising an equity round this fall to reach FDA clearance and market launch.
Visit https://healionics.com